Pharmacological modulation of connexin-formed channels in cardiac pathophysiology

British Journal of Pharmacology

Volumn 163, Issue 3, 2011, Pages 469-483

  De Vuyst, Elke ^a   Boengler, Kerstin ^b   Antoons, Gudrun ^c   Sipido, Karin R ^c   Schulz, Rainer ^d   Leybaert, Luc ^a,e  

^a GHENT UNIVERSITY   (Belgium)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d JUSTUS LIEBIG UNIVERSITY   (Germany)

^e NONE   (Belgium)

Author keywords

arrhythmia; cardiac ischaemia; connexins; gap junctions; hemichannels; peptides

Indexed keywords

AAP 10; ANTIARRHYTHMIC PEPTIDE; ANTIARRHYTHMIC PEPTIDE 10; ARGINYLARGINYLLYSYL (4 HYDROXYL BENZOYL); CALCIUM CHANNEL; CONNEXIN 37; CONNEXIN 40; CONNEXIN 43; CONNEXIN 45; CYCLOARGINYLARGINYLPROLYLPROLYLTYROSYLARGINYLGLYCINE; DANEGAPTIDE; DIGOXIN; GAP JUNCTION PROTEIN; HP 5; METOPROLOL; PLACEBO; POTASSIUM CHANNEL; ROTIGAPTIDE; SERYLARGINYLPROLYLTHREONYLGLUTAMYLLYSYLTHREONYLI; SERYLARGINYLPROLYLTHREONYLGLUTAMYLLYSYLTHREONYLISOLEUCYLPHENYLALANYLISOLEUCYLISOLEUCINE; SERYLASPARTYLASPARTYLLEUCYLARGINYLSERYLPROLYLGLUTAMINYLLEUCYLHISTIDYLASPARAGINYLGLUTAMYLGLUTAMYLGLUTAMYLSERYLALANYLVALYLPROLYLPHENYLALANYLTYROSYLSERYLHISTIDYLSERYLHISTIDYLMETHIONYLVALYLARGINYLARGINYLLYSYLPROLYLARGINYLASPARAGINYLPROLYLARGININE; SODIUM CHANNEL; UNCLASSIFIED DRUG; VALYLCYSTYLTYROSYLGLTAMYLLYSYLSERYLPHENYLALANYLPROLYLISOLEUCYLSERYLHISTIDYLVALYLARGININE; ZP 2519;

ANISOTROPY; BINDING SITE; CELL COMMUNICATION; CELL SURVIVAL; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; ENZYME ACTIVATION; EXCITATION CONTRACTION COUPLING; GAP JUNCTION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART CONDUCTION; HEART FAILURE; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART REPOLARIZATION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; PATCH CLAMP; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SINGLE DRUG DOSE; UNSTABLE ANGINA PECTORIS;

EID: 79953705138     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01244.x     Document Type: Review

References (139)

1. Andrade-Rozental AF, Rozental R, Hopperstad MG, Wu JK, Vrionis FD, Spray DC, (2000). Gap junctions: the 'kiss of death' and the 'kiss of life'. Brain Res Brain Res Rev 32: 308-315.
2. Aonuma S, Kohama Y, Akai K, Komiyama Y, Nakajima S, Wakabayashi M, et al,. (1980). Studies on heart. XIX. Isolation of an atrial peptide that improves the rhythmicity of cultured myocardial cell clusters. Chem Pharm Bull (Tokyo) 28: 3332-3339. (Pubitemid 11169094)
3. Aonuma S, Kohama Y, Makino T, Fujisawa Y, (1982). Studies of heart. XXI. Amino acid sequence of antiarrhythmic peptide (AAP) isolated from atria. J Pharmacobiodyn 5: 40-48. (Pubitemid 12127549)
4. Aonuma S, Kohama Y, Makino T, Yoshitake I, Hattori K, Morikawa K, et al,. (1983). Studies on heart. XXIII. Distribution of [1-14C] acetamidino- antiarrhythmic peptide (14C-AAP) in mice. Chem Pharm Bull (Tokyo) 31: 612-619. (Pubitemid 13080818)
5. Axelsen LN, Stahlhut M, Mohammed S, Larsen BD, Nielsen MS, Holstein-Rathlou NH, et al,. (2006). Identification of ischemia-regulated phosphorylation sites in connexin43: a possible target for the antiarrhythmic peptide analogue rotigaptide (ZP123). J Mol Cell Cardiol 40: 790-798. (Pubitemid 43817040)
6. Beardslee MA, Lerner DL, Tadros PN, Laing JG, Beyer EC, Yamada KA, et al,. (2000). Dephosphorylation and intracellular redistribution of ventricular connexin43 during electrical uncoupling induced by ischemia. Circ Res 87: 656-662.
7. Bigger JT, Breithardt G, Brown AM, Camm AJ, Carmeliet E, Fozzard HA, et al,. (1991). The 'Sicilian Gambit'. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. The Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. Eur Heart J 12: 1112-1131.
8. Boengler K, Dodoni G, Rodriguez-Sinovas A, Cabestrero A, Ruiz-Meana M, Gres P, et al,. (2005). Connexin 43 in cardiomyocyte mitochondria and its increase by ischemic preconditioning. Cardiovasc Res 67: 234-244. (Pubitemid 40943616)
9. Braet K, Aspeslagh S, Vandamme W, Willecke K, Martin PE, Evans WH, et al,. (2003a). Pharmacological sensitivity of ATP release triggered by photoliberation of inositol-1,4,5-trisphosphate and zero extracellular calcium in brain endothelial cells. J Cell Physiol 197: 205-213. (Pubitemid 37485249)
10. Braet K, Vandamme W, Martin PE, Evans WH, Leybaert L, (2003b). Photoliberating inositol-1,4,5-trisphosphate triggers ATP release that is blocked by the connexin mimetic peptide gap 26. Cell Calcium 33: 37-48. (Pubitemid 36230881)
11. Brisset AC, Isakson BE, Kwak BR, (2009). Connexins in vascular physiology and pathology. Antioxid Redox Signal 11: 267-282.
12. Bukauskas FF, Kreuzberg MM, Rackauskas M, Bukauskiene A, Bennett MV, Verselis VK, et al,. (2006). Properties of mouse connexin 30.2 and human connexin 31.9 hemichannels: implications for atrioventricular conduction in the heart. Proc Natl Acad Sci USA 103: 9726-9731. (Pubitemid 43955892)
13. Burnstock G, (2006). Purinergic signalling. Br J Pharmacol 147 (Suppl. 1): S172-S181. (Pubitemid 43077275)
14. Butera JA, Larsen BD, Hennan JK, Kerns E, Di L, Alimardanov A, et al,. (2009). Discovery of (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2- carboxylic acid hydrochloride (GAP-134)13, an orally active small molecule gap-junction modifier for the treatment of atrial fibrillation. J Med Chem 52: 908-911.
15. Camelliti P, Green CR, Kohl P, (2006). Structural and functional coupling of cardiac myocytes and fibroblasts. Adv Cardiol 42: 132-149. (Pubitemid 43805861)
16. Cascio WE, Yang H, Johnson TA, Muller-Borer BJ, Lemasters JJ, (2001). Electrical properties and conduction in reperfused papillary muscle. Circ Res 89: 807-814. (Pubitemid 34633852)
17. Christ GJ, Spektor M, Brink PR, Barr L, (1999). Further evidence for the selective disruption of intercellular communication by heptanol. Am J Physiol 276: H1911-H1917. (Pubitemid 29323474)
18. Clarke TC, Williams OJ, Martin PE, Evans WH, (2009). ATP release by cardiac myocytes in a simulated ischaemia model: inhibition by a connexin mimetic and enhancement by an antiarrhythmic peptide. Eur J Pharmacol 605: 9-14.
19. Crow DS, Beyer EC, Paul DL, Kobe SS, Lau AF, (1990). Phosphorylation of connexin43 gap junction protein in uninfected and Rous sarcoma virus-transformed mammalian fibroblasts. Mol Cell Biol 10: 1754-1763.
20. Darbar D, Roden DM, (2006). Future of antiarrhythmic drugs. Curr Opin Cardiol 21: 361-367. (Pubitemid 44315070)
21. De Mello WC, (1987). Cell-to-cell coupling assayed by means of electrical measurements. Experientia 43: 1075-1079. (Pubitemid 18017010)
22. De Vuyst E, Wang N, Decrock E, De Bock M, Vinken M, Van Moorhem M, et al,. (2009). Ca(2+) regulation of connexin 43 hemichannels in C6 glioma and glial cells. Cell Calcium 46: 176-187.
23. Decrock E, De Vuyst E, Vinken M, Van Moorhem M, Vranckx K, Wang N, et al,. (2009a). Connexin 43 hemichannels contribute to the propagation of apoptotic cell death in a rat C6 glioma cell model. Cell Death Diff 16: 151-163.
24. Decrock E, Vinken M, De Vuyst E, Krysko DV, D'Herde K, Vanhaecke T, et al,. (2009b). Connexin-related signaling in cell death: to live or let die? Cell Death Diff 16: 524-536.
25. Dhein S, (2002). Peptides acting at gap junctions. Peptides 23: 1701-1709. (Pubitemid 35246290)
26. Dhein S, (2006). Cardiac ischemia and uncoupling: gap junctions in ischemia and infarction. Adv Cardiol 42: 198-212. (Pubitemid 43805865)
27. Dhein S, Manicone N, Muller A, Gerwin R, Ziskoven U, Irankhahi A, et al,. (1994). A new synthetic antiarrhythmic peptide reduces dispersion of epicardial activation recovery interval and diminishes alterations of epicardial activation patterns induced by regional ischemia. A mapping study. Naunyn Schmiedebergs Arch Pharmacol 350: 174-184. (Pubitemid 24248377)
28. Dhein S, Weng S, Grover R, Tudyka T, Gottwald M, Schaefer T, et al,. (2001). Protein kinase Calpha mediates the effect of antiarrhythmic peptide on gap junction conductance. Cell Commun Adhes 8: 257-264.
29. Dhein S, Larsen BD, Petersen JS, Mohr FW, (2003). Effects of the new antiarrhythmic peptide ZP123 on epicardial activation and repolarization pattern. Cell Commun Adhes 10: 371-378. (Pubitemid 38081400)
30. Dhein S, Hagen A, Jozwiak J, Dietze A, Garbade J, Barten M, et al,. (2009). Improving cardiac gap junction communication as a new antiarrhythmic mechanism: the action of antiarrhythmic peptides. Naunyn Schmiedebergs Arch Pharmacol 381: 221-234.
31. Doble BW, Ping P, Kardami E, (2000). The epsilon subtype of protein kinase C is required for cardiomyocyte connexin-43 phosphorylation. Circ Res 86: 293-301. (Pubitemid 30108823)
32. Dorian P, Zhong J, So PSS, Debicki D, Hennan JK, (2005). Increasing gap junction conductance with ZP123 improves defibrillation success in experimental cardiac arrest. In American Heart Association. pp. II-115. Abstract No. 637. Dallas, Texas, USA Circulation.
33. Duffy HS, (2008). Cardiac connections-the antiarrhythmic solution? N Engl J Med 358: 1397-1398.
34. Ek-Vitorin JF, King TJ, Heyman NS, Lampe PD, Burt JM, (2006). Selectivity of connexin 43 channels is regulated through protein kinase C-dependent phosphorylation. Circ Res 98: 1498-1505. (Pubitemid 44297072)
35. Elias LA, Kriegstein AR, (2008). Gap junctions: multifaceted regulators of embryonic cortical development. Trends Neurosci 31: 243-250.
36. Eloff BC, Gilat E, Wan X, Rosenbaum DS, (2003). Pharmacological modulation of cardiac gap junctions to enhance cardiac conduction: evidence supporting a novel target for antiarrhythmic therapy. Circulation 108: 3157-3163. (Pubitemid 38031807)
37. Eltzschig HK, Eckle T, Mager A, Kuper N, Karcher C, Weissmuller T, et al,. (2006). ATP release from activated neutrophils occurs via connexin 43 and modulates adenosine-dependent endothelial cell function. Circ Res 99: 1100-1108. (Pubitemid 44729934)
38. Evans WH, Boitano S, (2001). Connexin mimetic peptides: specific inhibitors of gap-junctional intercellular communication. Biochem Soc Trans 29: 606-612. (Pubitemid 32783666)
39. Evans WH, De Vuyst E, Leybaert L, (2006). The gap junction cellular internet: connexin hemichannels enter the signalling limelight. Biochem J 397: 1-14. (Pubitemid 44032830)
40. Fox KA, Clayton TC, Damman P, Pocock SJ, de Winter RJ, Tijssen JG, et al,. (2010). Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. J Am Coll Cardiol 55: 2435-2445.
41. Garcia-Dorado D, Inserte J, Ruiz-Meana M, Gonzalez MA, Solares J, Julia M, et al,. (1997). Gap junction uncoupler heptanol prevents cell-to-cell progression of hypercontracture and limits necrosis during myocardial reperfusion. Circulation 96: 3579-3586. (Pubitemid 27513436)
42. Garcia-Dorado D, Ruiz-Meana M, Padilla F, Rodriguez-Sinovas A, Mirabet M, (2002). Gap junction-mediated intercellular communication in ischemic preconditioning. Cardiovasc Res 55: 456-465. (Pubitemid 34874940)
43. Grover R, Dhein S, (1998). Spatial structure determination of antiarrhythmic peptide using nuclear magnetic resonance spectroscopy. Peptides 19: 1725-1729. (Pubitemid 29032060)
44. Grover R, Dhein S, (2001). Structure-activity relationships of novel peptides related to the antiarrhythmic peptide AAP10 which reduce the dispersion of epicardial action potential duration. Peptides 22: 1011-1021. (Pubitemid 32614122)
45. Gysembergh A, Kloner RA, Przyklenk K, (2001). Pretreatment with the gap junction uncoupler heptanol does not limit infarct size in rabbit heart. Cardiovasc Pathol 10: 13-17. (Pubitemid 32409985)
46. Hagen A, Dietze A, Dhein S, (2009). Human cardiac gap-junction coupling: effects of antiarrhythmic peptide AAP10. Cardiovasc Res 83: 405-415.
47. Hatanaka K, Kawata H, Toyofuku T, Yoshida K, (2004). Down-regulation of connexin43 in early myocardial ischemia and protective effect by ischemic preconditioning in rat hearts in vivo. Jpn Heart J 45: 1007-1019. (Pubitemid 40528871)
48. Haugan K, Kjolbye AL, Hennan JK, Petersen JS, (2005a). Rotigaptide (ZP123) reverts established atrial conduction velocity slowing. Cell Commun Adhes 12: 271-278.
49. Haugan K, Olsen KB, Hartvig L, Petersen JS, Holstein-Rathlou NH, Hennan JK, et al,. (2005b). The antiarrhythmic peptide analog ZP123 prevents atrial conduction slowing during metabolic stress. J Cardiovasc Electrophysiol 16: 537-545. (Pubitemid 40632487)
50. Haugan K, Marcussen N, Kjolbye AL, Nielsen MS, Hennan JK, Petersen JS, (2006). Treatment with the gap junction modifier rotigaptide (ZP123) reduces infarct size in rats with chronic myocardial infarction. J Cardiovasc Pharmacol 47: 236-242. (Pubitemid 44384062)
51. Hawat G, Baroudi G, (2009). Selective inhibition of connexin 43 hemichannels by Gap26 confers cardioprotection against myocardial ischemia injury: in vivo study. Circulation 120: S839.
52. Hawat G, Benderdour M, Rousseau G, Baroudi G, (2010). Connexin 43 mimetic peptide Gap26 confers protection to intact heart against myocardial ischemia injury. Pflugers Arch 460: 583-592.
53. Hennan JK, Swillo RE, Morgan GA, Keith JC, Jr, Schaub RG, Smith RP, et al,. (2006). Rotigaptide (ZP123) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs. J Pharmacol Exp Ther 317: 236-243.
54. Hennan JK, Swillo RE, Morgan GA, Rossman EI, Kantrowitz J, Butera J, et al,. (2009). GAP-134 ([2S,4R]-1-[2-aminoacetyl]4-benzamidopyrrolidine-2- carboxylic acid) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs. J Cardiovasc Pharmacol Ther 14: 207-214.
55. Issa Z, Miller JM, Zipes DP, (2009). Clinical Arrhythmology and Electrophysiology: A Companion to Braunwald's Heart Disease., Issa Z, (ed.). Elsevier: Philadelphia, PA, p. 487.
56. Jeyaraman M, Tanguy S, Fandrich RR, Lukas A, Kardami E, (2003). Ischemia-induced dephosphorylation of cardiomyocyte connexin-43 is reduced by okadaic acid and calyculin A but not fostriecin. Mol Cell Biochem 242: 129-134. (Pubitemid 36240538)
57. John S, Cesario D, Weiss JN, (2003). Gap junctional hemichannels in the heart. Acta Physiol Scand 179: 23-31. (Pubitemid 37083059)
58. Jorgensen NR, Teilmann SC, Henriksen Z, Meier E, Hansen SS, Jensen JE, et al,. (2005). The antiarrhythmic peptide analog rotigaptide (ZP123) stimulates gap junction intercellular communication in human osteoblasts and prevents decrease in femoral trabecular bone strength in ovariectomized rats. Endocrinology 146: 4745-4754. (Pubitemid 41446612)
59. Jozwiak J, Dhein S, (2008). Local effects and mechanisms of antiarrhythmic peptide AAP10 in acute regional myocardial ischemia: electrophysiological and molecular findings. Naunyn Schmiedebergs Arch Pharmacol 378: 459-470.
60. Kandouz M, Batist G, (2010). Gap junctions and connexins as therapeutic targets in cancer. Expert Opin Ther Targets 14: 681-692.
61. Kang J, Kang N, Lovatt D, Torres A, Zhao Z, Lin J, et al,. (2008). Connexin 43 hemichannels are permeable to ATP. J Neurosci 28: 4702-4711.
62. Kim D, Jeon C, Kim JH, Kim MS, Yoon CH, Choi IS, et al,. (2006). Cytoplasmic transduction peptide (CTP): new approach for the delivery of biomolecules into cytoplasm in vitro and in vivo. Exp Cell Res 312: 1277-1288.
63. Kjolbye AL, Kanters JK, Holstein-Rathlou NH, Petersen JS, (2000). The antiarrhytmic peptide HPP-5 reduces APD90 dispersion and prevents ventricular fibrillation in isolated perfused rabbit hearts. FASEB J 14: A698.
64. Kjolbye AL, Holstein-Rathlou NH, Petersen JS, (2002). Anti-arrhythmic peptide N-3-(4-hydroxyphenyl)propionyl Pro-Hyp-Gly-Ala-Gly-OH reduces dispersion of action potential duration during ischemia/reperfusion in rabbit hearts. J Cardiovasc Pharmacol 40: 770-779. (Pubitemid 36109295)
65. Kjolbye AL, Knudsen CB, Jepsen T, Larsen BD, Petersen JS, (2003). Pharmacological characterization of the new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH2 (ZP123): in vivo and in vitro studies. J Pharmacol Exp Ther 306: 1191-1199. (Pubitemid 37028306)
66. Kjolbye AL, Eloff BC, Rosenbaum DS, (2005). Maintenance of intercellular coupling by ZP123 suppresses arrhytmogenic discordant alternans. Circulation 108 (Suppl. IV): 292.
67. Kjolbye AL, Haugan K, Hennan JK, Petersen JS, (2007). Pharmacological modulation of gap junction function with the novel compound rotigaptide: a promising new principle for prevention of arrhythmias. Basic Clin Pharmacol Toxicol 101: 215-230. (Pubitemid 350194808)
68. Kleber AG, Rudy Y, (2004). Basic mechanisms of cardiac impulse propagation and associated arrhythmias. Physiol Rev 84: 431-488. (Pubitemid 38365490)
69. Kleber AG, Riegger CB, Janse MJ, (1987). Electrical uncoupling and increase of extracellular resistance after induction of ischemia in isolated, arterially perfused rabbit papillary muscle. Circ Res 61: 271-279. (Pubitemid 17137122)
70. Kohama Y, Okimoto N, Mimura T, Fukaya C, Watanabe M, Yokoyama K, (1987). A new antiarrhythmic peptide, N-3-(4-hydroxyphenyl)propionyl Pro-Hyp-Gly-Ala-Gly. Chem Pharm Bull (Tokyo) 35: 3928-3930. (Pubitemid 18076887)
71. Kondo RP, Wang SY, John SA, Weiss JN, Goldhaber JI, (2000). Metabolic inhibition activates a non-selective current through connexin hemichannels in isolated ventricular myocytes. J Mol Cell Cardiol 32: 1859-1872.
72. Laird DW, (2006). Life cycle of connexins in health and disease. Biochem J 394: 527-543.
73. Lampe PD, Lau AF, (2000). Regulation of gap junctions by phosphorylation of connexins. Arch Biochem Biophys 384: 205-215. (Pubitemid 32012794)
74. Lampe PD, Cooper CD, King TJ, Burt JM, (2006). Analysis of Connexin43 phosphorylated at S325, S328 and S330 in normoxic and ischemic heart. J Cell Sci 119: 3435-3442. (Pubitemid 44405227)
75. Laurent G, Leong-Poi H, Mangat I, Moe GW, Hu X, So PP, et al,. (2009). Effects of chronic gap junction conduction-enhancing antiarrhythmic peptide GAP-134 administration on experimental atrial fibrillation in dogs. Circ Arrhythm Electrophysiol 2: 171-178.
76. Lerner DL, Yamada KA, Schuessler RB, Saffitz JE, (2000). Accelerated onset and increased incidence of ventricular arrhythmias induced by ischemia in Cx43-deficient mice. Circulation 101: 547-552. (Pubitemid 30080870)
77. Lewandowski R, Procida K, Vaidyanathan R, Coombs W, Jalife J, Nielsen MS, et al,. (2008). RXP-E: a connexin43-binding peptide that prevents action potential propagation block. Circ Res 103: 519-526.
78. Leybaert L, Braet K, Vandamme W, Cabooter L, Martin PE, Evans WH, (2003). Connexin channels, connexin mimetic peptides and ATP release. Cell Commun Adhes 10: 251-257. (Pubitemid 38081381)
79. Li G, Whittaker P, Yao M, Kloner RA, Przyklenk K, (2002). The gap junction uncoupler heptanol abrogates infarct size reduction with preconditioning in mouse hearts. Cardiovasc Pathol 11: 158-165. (Pubitemid 34553415)
80. Lin JH, Weigel H, Cotrina ML, Liu S, Bueno E, Hansen AJ, et al,. (1998). Gap-junction-mediated propagation and amplification of cell injury. Nat Neurosci 1: 494-500.
81. Liu F, Arce FT, Ramachandran S, Lal R, (2006). Nanomechanics of hemichannel conformations: connexin flexibility underlying channel opening and closing. J Biol Chem 281: 23207-23217.
82. McCallister LP, Trapukdi S, Neely JR, (1979). Morphometric observations on the effects of ischemia in the isolated perfused rat heart. J Mol Cell Cardiol 11: 619-630. (Pubitemid 9233865)
83. Matsumura K, Mayama T, Lin H, Sakamoto Y, Ogawa K, Imanaga I, (2006). Effects of cyclic AMP on the function of the cardiac gap junction during hypoxia. Exp Clin Cardiol 11: 286-293. (Pubitemid 44932425)
84. Miro-Casas E, Ruiz-Meana M, Agullo E, Stahlhofen S, Rodriguez-Sinovas A, Cabestrero A, et al,. (2009). Connexin43 in cardiomyocyte mitochondria contributes to mitochondrial potassium uptake. Cardiovasc Res 83: 747-756.
85. Miura T, Ohnuma Y, Kuno A, Tanno M, Ichikawa Y, Nakamura Y, et al,. (2004). Protective role of gap junctions in preconditioning against myocardial infarction. Am J Physiol 286: H214-H221. (Pubitemid 38049482)
86. Miura T, Yano T, Naitoh K, Nishihara M, Miki T, Tanno M, et al,. (2007). Delta-opioid receptor activation before ischemia reduces gap junction permeability in ischemic myocardium by PKC-epsilon-mediated phosphorylation of connexin 43. Am J Physiol Heart Circ Physiol 293: H1425-H1431. (Pubitemid 47367185)
87. Miura T, Miki T, Yano T, (2010). Role of the gap junction in ischemic preconditioning in the heart. Am J Physiol 298: H1115-H1125.
88. Muller A, Gottwald M, Tudyka T, Linke W, Klaus W, Dhein S, (1997a). Increase in gap junction conductance by an antiarrhythmic peptide. Eur J Pharmacol 327: 65-72. (Pubitemid 27220222)
89. Muller A, Schaefer T, Linke W, Tudyka T, Gottwald M, Klaus W, et al,. (1997b). Actions of the antiarrhythmic peptide AAP10 on intercellular coupling. Naunyn Schmiedebergs Arch Pharmacol 356: 76-82. (Pubitemid 27276893)
90. Musil LS, Goodenough DA, (1991). Biochemical analysis of connexin43 intracellular transport, phosphorylation, and assembly into gap junctional plaques. J Cell Biol 115: 1357-1374. (Pubitemid 21909980)
91. Naccarelli GV, Wolbrette DL, Patel HM, Luck JC, (2000). Amiodarone: clinical trials. Curr Opin Cardiol 15: 64-72. (Pubitemid 30055222)
92. Naitoh K, Ichikawa Y, Miura T, Nakamura Y, Miki T, Ikeda Y, et al,. (2006). MitoKATP channel activation suppresses gap junction permeability in the ischemic myocardium by an ERK-dependent mechanism. Cardiovasc Res 70: 374-383.
93. Naitoh K, Yano T, Miura T, Itoh T, Miki T, Tanno M, et al,. (2009). Roles of Cx43-associated protein kinases in suppression of gap junction-mediated chemical coupling by ischemic preconditioning. Am J Physiol 296: H396-H403.
94. Navarro-Lopez F, Cosin J, Marrugat J, Guindo J, Bayes de Luna A, (1993). Comparison of the effects of amiodarone versus metoprolol on the frequency of ventricular arrhythmias and on mortality after acute myocardial infarction. SSSD Investigators. Spanish Study on Sudden Death. Am J Cardiol 72: 1243-1248. (Pubitemid 23357784)
95. Ovize M, Baxter GF, Di Lisa F, Ferdinandy P, Garcia-Dorado D, Hausenloy DJ, et al,. (2010). Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 87: 406-423.
96. Passman R, Kadish A, (2001). Polymorphic ventricular tachycardia, long Q-T syndrome, and torsades de pointes. Med Clin North Am 85: 321-341. (Pubitemid 32176430)
97. Peters NS, Coromilas J, Severs NJ, Wit AL, (1997). Disturbed connexin43 gap junction distribution correlates with the location of reentrant circuits in the epicardial border zone of healing canine infarcts that cause ventricular tachycardia. Circulation 95: 988-996. (Pubitemid 27091545)
98. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al,. (2003). Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349: 1893-1906. (Pubitemid 37409706)
99. Piatnitski Chekler EL, Butera JA, Di L, Swillo RE, Morgan GA, Rossman EI, et al,. (2009). Discovery of a class of potent gap-junction modifiers as novel antiarrhythmic agents. Bioorg Med Chem Lett 19: 4551-4554.
100. Pogwizd SM, Schlotthauer K, Li L, Yuan W, Bers DM, (2001). Arrhythmogenesis and contractile dysfunction in heart failure: Roles of sodium-calcium exchange, inward rectifier potassium current, and residual beta-adrenergic responsiveness. Circ Res 88: 1159-1167. (Pubitemid 34132516)
101. Priori SG, Aliot E, Blomstrom-Lundqvist C, Bossaert L, Breithardt G, Brugada P, et al,. (2003). Update of the guidelines on sudden cardiac death of the European Society of Cardiology. Eur Heart J 24: 13-15. (Pubitemid 36109541)
102. Przyklenk K, Maynard M, Darling CE, Whittaker P, (2005). Pretreatment with d-myo-inositol trisphosphate reduces infarct size in rabbit hearts: role of inositol trisphosphate receptors and gap junctions in triggering protection. J Pharmacol Exp Ther 314: 1386-1392. (Pubitemid 41206006)
103. Qi X, Varma P, Newman D, Dorian P, (2001). Gap junction blockers decrease defibrillation thresholds without changes in ventricular refractoriness in isolated rabbit hearts. Circulation 104: 1544-1549. (Pubitemid 32917349)
104. Qin H, Walcott GP, Killingsworth CR, Rollins DL, Smith WM, Ideker RE, (2002). Impact of myocardial ischemia and reperfusion on ventricular defibrillation patterns, energy requirements, and detection of recovery. Circulation 105: 2537-2542. (Pubitemid 34568977)
105. Quan XQ, Bai R, Lu JG, Patel C, Liu N, Ruan Y, et al,. (2009). Pharmacological enhancement of cardiac gap junction coupling prevents arrhythmias in canine LQT2 model. Cell Commun Adhes 1-10.
106. Ren Y, Zhang CT, Wu J, Ruan YF, Pu J, He L, et al,. (2006). [The effects of antiarrhythmic peptide AAP10 on ventricular arrhythmias in rabbits with healed myocardial infarction]. Zhonghua Xin Xue Guan Bing Zhi [Chin J Cardiovasc Dis] 34: 825-828.
107. Rodriguez-Sinovas A, Garcia-Dorado D, Ruiz-Meana M, Soler-Soler J, (2006). Protective effect of gap junction uncouplers given during hypoxia against reoxygenation injury in isolated rat hearts. Am J Physiol 290: H648-H656.
108. Rossman EI, Liu K, Morgan GA, Swillo RE, Krueger JA, Gardell SJ, et al,. (2009). The gap junction modifier, GAP-134 [(2S,4R)-1-(2-aminoacetyl)-4- benzamido-pyrrolidine-2-carboxylic acid], improves conduction and reduces atrial fibrillation/flutter in the canine sterile pericarditis model. J Pharmacol Exp Ther 329: 1127-1133.
109. Rottlaender D, Boengler K, Wolny M, Michels G, Endres-Becker J, Motloch LJ, et al,. (2010). Connexin 43 acts as a cytoprotective mediator of signal transduction by stimulating mitochondrial KATP channels in mouse cardiomyocytes. J Clin Invest 120: 1441-1453.
110. Ruiz-Meana M, Garcia-Dorado D, Lane S, Pina P, Inserte J, Mirabet M, et al,. (2001). Persistence of gap junction communication during myocardial ischemia. Am J Physiol Heart Circ Physiol 280: H2563-H2571.
111. Saffitz JE, Schuessler RB, Yamada KA, (1999). Mechanisms of remodeling of gap junction distributions and the development of anatomic substrates of arrhythmias. Cardiovasc Res 42: 309-317. (Pubitemid 29243159)
112. Salameh A, Krautblatter S, Karl S, Blanke K, Gomez DR, Dhein S, et al,. (2009). The signal transduction cascade regulating the expression of the gap junction protein connexin43 by beta-adrenoceptors. Br J Pharmacol 158: 198-208.
113. Salameh A, Blanke K, Dhein S, Janousek J, (2010). Cardiac gap junction channels are upregulated by metoprolol: an unexpected effect of beta-blockers. Pharmacology 85: 203-210.
114. Schron EB, Exner DV, Yao Q, Jenkins LS, Steinberg JS, Cook JR, et al,. (2002). Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation 105: 589-594. (Pubitemid 34123433)
115. Severs NJ, Bruce AF, Dupont E, Rothery S, (2008). Remodelling of gap junctions and connexin expression in diseased myocardium. Cardiovasc Res 80: 9-19.
116. Shibayama J, Lewandowski R, Kieken F, Coombs W, Shah S, Sorgen PL, et al,. (2006). Identification of a novel peptide that interferes with the chemical regulation of connexin43. Circ Res 98: 1365-1372. (Pubitemid 43948060)
117. Shintani-Ishida K, Uemura K, Yoshida KI, (2007). Hemichannels in cardiomyocytes open transiently during ischemia and contribute to reperfusion injury following brief ischemia. Am J Physiol Heart Circ Physiol 293: H1714-H1720. (Pubitemid 47367219)
118. Sims JJ, Schoff KL, Loeb JM, Wiegert NA, (2003). Regional gap junction inhibition increases defibrillation thresholds. Am J Physiol Heart Circ Physiol 285: H10-H16. (Pubitemid 36736409)
119. Smith WT, Fleet WF, Johnson TA, Engle CL, Cascio WE, (1995). The Ib phase of ventricular arrhythmias in ischemic in situ porcine heart is related to changes in cell-to-cell electrical coupling. Experimental Cardiology Group, University of North Carolina. Circulation 92: 3051-3060.
120. Solan JL, Lampe PD, (2007). Key connexin 43 phosphorylation events regulate the gap junction life cycle. J Membr Biol 217: 35-41. (Pubitemid 350160003)
121. Solan JL, Lampe PD, (2009). Connexin43 phosphorylation: structural changes and biological effects. Biochem J 419: 261-272.
122. Solan JL, Marquez-Rosado L, Sorgen PL, Thornton PJ, Gafken PR, Lampe PD, (2007). Phosphorylation at S365 is a gatekeeper event that changes the structure of Cx43 and prevents down-regulation by PKC. J Cell Biol 179: 1301-1309. (Pubitemid 350277746)
123. Sorgen PL, Duffy HS, Spray DC, Delmar M, (2004). pH-dependent dimerization of the carboxyl terminal domain of Cx43. Biophys J 87: 574-581. (Pubitemid 38880110)
124. Stahlhut M, Petersen JS, Hennan JK, Ramirez MT, (2006). The antiarrhythmic peptide rotigaptide (ZP123) increases connexin 43 protein expression in neonatal rat ventricular cardiomyocytes. Cell Commun Adhes 13: 21-27.
125. Swenson KI, Piwnica-Worms H, McNamee H, Paul DL, (1990). Tyrosine phosphorylation of the gap junction protein connexin43 is required for the pp60v-src-induced inhibition of communication. Cell Regul 1: 989-1002.
126. Szybalska EH, Szybalski W, (1962). Genetics of human cess line. IV. DNA-mediated heritable transformation of a biochemical trait. Proc Natl Acad Sci USA 48: 2026-2034.
127. Trosko JE, (2007). Gap junctional intercellular communication as a biological 'Rosetta stone' in understanding, in a systems biological manner, stem cell behavior, mechanisms of epigenetic toxicology, chemoprevention and chemotherapy. J Membr Biol 218: 93-100. (Pubitemid 350132124)
128. Turner MS, Haywood GA, Andreka P, You L, Martin PE, Evans WH, et al,. (2004). Reversible connexin 43 dephosphorylation during hypoxia and reoxygenation is linked to cellular ATP levels. Circ Res 95: 726-733. (Pubitemid 39331933)
129. Udata C, Micalizzi M, Katz A, Giorgio QM, Meng X, (2006a). Six days continuous IV infusion study of the safety, tolerability and pharmacokinetics of rotigaptide (ZP123) adminstered intravenously to healthy subjects. Clin Pharmacol Ther 79: 77.
130. Udata C, Parks V, Patat AA, Fauchoux N, Meng X, (2006b). Absence of drug interaction between rotigaptide (ZP123) and digoxin. Clin Pharmacol Ther 79: 25.
131. Verma V, Larsen BD, Coombs W, Lin X, Spagnol G, Sorgen PL, et al,. (2009). Novel pharmacophores of connexin43 based on the 'RXP' series of Cx43-binding peptides. Circ Res 105: 176-184.
132. Verma V, Due Larsen B, Coombs W, Lin X, Sarrou E, Taffet SM, et al,. (2010). Design and characterization of the first peptidomimetic molecule that prevents acidification-induced closure of cardiac gap junctions. Heart Rhythm 7: 1491-1498.
133. Weiss JN, Chen PS, Qu Z, Karagueuzian HS, Garfinkel A, (2000). Ventricular fibrillation: how do we stop the waves from breaking? Circ Res 87: 1103-1107.
134. Weng S, Lauven M, Schaefer T, Polontchouk L, Grover R, Dhein S, (2002). Pharmacological modification of gap junction coupling by an antiarrhythmic peptide via protein kinase C activation. FASEB J 16: 1114-1116.
135. Wiegerinck RF, de Bakker JM, Opthof T, de Jonge N, Kirkels H, Wilms-Schopman FJ, et al,. (2009). The effect of enhanced gap junctional conductance on ventricular conduction in explanted hearts from patients with heart failure. Basic Res Cardiol 104: 321-332.
136. Willecke K, Eiberger J, Degen J, Eckardt D, Romualdi A, Guldenagel M, et al,. (2002). Structural and functional diversity of connexin genes in the mouse and human genome. Biol Chem 383: 725-737. (Pubitemid 34649891)
137. Xing D, Kjolbye AL, Nielsen MS, Petersen JS, Harlow KW, Holstein-Rathlou NH, et al,. (2003). ZP123 increases gap junctional conductance and prevents reentrant ventricular tachycardia during myocardial ischemia in open chest dogs. J Cardiovasc Electrophysiol 14: 510-520. (Pubitemid 36583913)
138. Zhang XS, Xiang BR, (2009). Discontinued drugs in 2008: cardiovascular drugs. Expert Opin Investig Drugs 18: 875-885.
139. Zipes DP, Wellens HJ, (1998). Sudden cardiac death. Circulation 98: 2334-2351. (Pubitemid 28533855)